Misaligned payment and quality incentives, Medicare Advantage practices, and workforce constraints can limit Medicare ...
The continuing launch of innovative but high-price drugs has intensified efforts by payers to manage use and spending and by pharmaceutical manufacturers to support patient access and sales. Payers ...
Experts discuss financial challenges of BTK inhibitor therapy. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results